GSK · Verdict

A summary of rules, not a profit forecast — don’t buy just because of a green verdict.

• ▲ P/E 17.3 vs peer median 46.0 — cheaper than peers
• ▲ P/S 2.2 vs peer median 5.5 — cheaper than peers
• ▲ FCF yield 6.4% vs peer median 2.8% — cheaper than peers
• ▲ Forward P/E 10.0 is below the current one — earnings growth expected

• ▲ Piotroski 9/9 — strong financial health
• ▲ ROE 28% — high return on equity
• ▼ Net margin fell: 51.0% → 17.5%
• ▲ Free cash flow positive every year

• ▼ Earnings per share falls -27.6% per year (3 y)

• ▼ Over 6 mo weaker than its sector (XLV) by 32%
• ▼ Price below SMA200 — long-term downtrend
• ▼ SMA50 below SMA200 — trend down
• ▼ Over a year +5% vs S&P 500 +11% — weaker than the market

• ▲ Risk/reward 1:2.4 — the target is farther than the stop
• ▼ Volatility 26% per year — much higher than the market (13%)

• ▲ Mean analyst target +19% from the current price

• ▲ S&P 500 above SMA200 — the market is in an uptrend
• ▲ Sector (XLV) above SMA200 — in an uptrend
• ▲ Sector (XLV) over 3 mo is stronger than the market by 11%